AstraZeneca spikes; receives approval for importing diabetes drug

The stock of AstraZeneca Pharma India was trading higher by 3.47% at Rs. 979.85 per share. The stock opened at Rs. 974.00 on Wednesday. The stock has shown a trend reversal after two days of consecutive fall.

The company informed the exchanges that it has received import and market permission through Form 45 from the Drug Controller General of India (DCGI) for FDC (Xigduo XR) of Dapagliflozin plus Metformin Hydrochloride, extended-release tablets.

The medication Xigduo XR tablet is indicated for the treatment of patients with Type 2 diabetes mellitus as an adjunct to diet and exercise regime to improve glycemic levels. The mediation will provide physicians with an advanced treatment option for managing potential weight loss and reduce the risk of hypoglycemia.

AstraZeneca Pharma India Limited is biopharmaceutical company that engages in manufacturing, sales and marketing activities of the company. The company has an extensive portfolio in various areas of healthcare including cardiovascular, metabolic diseases, oncology and respiratory.